Cardiol Therapeutics (TSX:CRDL) EBIT per Share : C$-0.47 (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics EBIT per Share?

Cardiol Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was C$-0.13. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.47.

During the past 3 years, the average EBIT per Share Growth Rate was 12.60% per year. During the past 5 years, the average EBIT per Share Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cardiol Therapeutics's EBIT per Share or its related term are showing as below:

TSX:CRDL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -114.7 Med: -14.5 Max: 12.6
Current: 12.6

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Cardiol Therapeutics was 12.60% per year. The lowest was -114.70% per year. And the median was -14.50% per year.

TSX:CRDL's 3-Year EBIT Growth Rate is ranked better than
57.19% of 862 companies
in the Drug Manufacturers industry
Industry Median: 7.35 vs TSX:CRDL: 12.60

Cardiol Therapeutics's EBIT for the three months ended in Mar. 2024 was C$-8.41 Mil.

Cardiol Therapeutics EBIT per Share Historical Data

The historical data trend for Cardiol Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics EBIT per Share Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.53

-0.69

-0.90

-0.66

-0.46

Cardiol Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.12	-0.10	-0.12	-0.12	-0.13

Cardiol Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cardiol Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-29.786	/	64.463
=	-0.46

Cardiol Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.405	/	67.259
=	-0.12

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.47

Cardiol Therapeutics (TSX:CRDL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cardiol Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer